Pozanicline
Pozanicline (ABT-089) is a drug developed by Abbott, that has nootropic and neuroprotective effects. Animal studies suggested it useful for the treatment of ADHD and subsequent human trials have shown ABT-089 to be effective for this application. It binds with high affinity subtype-selective to the α4β2 nicotinic acetylcholine receptors and has partial agonism to the α6β2 subtype, but not the α7 and α3β4 subtypes familiar to nicotine. It has particularly low tendency to cause side effects compared to other drugs in the class -making it an exciting candidate for clinical development.
Wikipage redirect
primaryTopic
Pozanicline
Pozanicline (ABT-089) is a drug developed by Abbott, that has nootropic and neuroprotective effects. Animal studies suggested it useful for the treatment of ADHD and subsequent human trials have shown ABT-089 to be effective for this application. It binds with high affinity subtype-selective to the α4β2 nicotinic acetylcholine receptors and has partial agonism to the α6β2 subtype, but not the α7 and α3β4 subtypes familiar to nicotine. It has particularly low tendency to cause side effects compared to other drugs in the class -making it an exciting candidate for clinical development.
has abstract
Pozanicline (ABT-089) is a dru ...... date for clinical development.
@en
CAS number
161417-03-4
FDA UNII code
CL2002R563
IUPAC name
2-methyl-3-([(2S)-pyrrolidin-2-yl]methoxy)pyridine
@en
PubChem
thumbnail
Wikipage page ID
17,716,446
Wikipage revision ID
723,776,282
ChemSpiderID
molecular weight
1.92258e+2
smiles
CC1=COC[C@@H]2CCCN2
StdInChIKey
YRVIKLBSVVNSHF-JTQLQIEISA-N
verifiedrevid
448,113,772
hypernym
comment
Pozanicline (ABT-089) is a dru ...... date for clinical development.
@en
label
Pozanicline
@en